Primmune Therapeutics Announces Close of Series A Financing
PRIVATEJan 12, 2021
Round Type
Series A
San DiegoBiotechnologyHealthcare
Description
Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonist as a therapeutic-adjuvant for acute viral diseases and cancer.
Who to call at Primmune Therapeutics, and when
A new round usually means Primmune Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Primmune Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Primmune Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Primmune Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Primmune Therapeutics
Location
San Diego, California, United States
About
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Primmune Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealthcare